AI 热点

Demis Hassabis 创立的 Isomorphic Labs 完成 50 亿美元 C 轮融资

CNBC Technology更新于 11月17日 22:53

Demis Hassabis’ AI company raises $5 billion, months after he left as Google DeepMind CEO

AI 导读

Isomorphic Labs 完成 50 亿美元 C 轮融资,由 Greenoaks 和 Sequoia Capital 联合领投,Andreessen Horowitz 参与,Alphabet 也出资。资金将用于用 AI 设计和开发新药,推进基础生物学模型、疾病理解和首批治疗项目进入临床试验。这轮融资距 Hassabis 卸任 Google DeepMind CEO 约三个半月,公司上一轮为 5 月的 21 亿美元 B 轮;据 Dealroom,2026 年药物发现初创累计融资 232 亿美元,创下纪录。

推荐理由

AI 评分 52

融资规模与投资方结构之外,原文还给出2026年药物发现初创累计融资23.2亿美元的纪录数据,可作为判断AI制药资本热度的参照。

主题

标签

正文

Isomorphic Labs, an artificial intelligence drug discovery startup founded by former Google DeepMind chief Demis Hassabis, has raised a $5 billion Series C, the company said on Tuesday.

Isomorphic's round comes three-and-a-half months after Hassabis stepped back as CEO of DeepMind, Google's AI lab, which he co-founded before the Big Tech giant acquired it in 2014.

The round was co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz, with investment from Alphabet, Google's parent. The fresh funds will help fund the design and development of new medicines using AI.

Drug discovery startups have seen record funding poured into them by investors in 2026 as companies look to capitalize on advances in AI. OpenAI and Anthropic have also been investing in tools to develop new medicines using the technology.

Hassabis has been CEO of Isomorphic Labs since the startup spun out of DeepMind in 2021.

"When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI," said Hassabis.

"This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients," he added.

Isomorphic is building a proprietary drug design engine and therapeutic candidate pipeline designed with AI, which it says will help it deliver the next generation of medicines.

Anthropic announced it was launching an AI drug discovery program in June and OpenAI partnered with Novo Nordisk in April.

Drug discovery startups have raised $23.2 billion in 2026, according to deal-counting platform Dealroom, a record figure.

Isomorphic last raised in May, with a $2.1 billion Series B.Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

来源

CNBC Technology